INGN 225

DB05325InvestigationalProtein Based Therapies

INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2... INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.

Mechanism: Pharmacologically active on Cellular tumor antigen p53
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer, head and neck cancer, and lung cancer.Curator reviewed
Code names: INGN 225

Resolves to

Targets

P04637TP53

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

290Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with INGN 225, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account